Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-type RAS metastatic colorectal cancer

Abstract

Objective:

To compare the costs of first-line treatment with panitumumab?+?FOLFOX in comparison to cetuximab?+?FOLFIRI among patients with wild-type (WT) RAS metastatic colorectal cancer (mCRC) in the US.     

Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting

Abstract

Objective:

The 21-gene assay (Oncotype DX Breast Cancer Test (Genomic Health Inc., Redwood City, CA)) is a well validated test that predicts the likelihood of adjuvant chemotherapy benefit and the 10-year risk of distant recurrence in patients with ER+, HER2? early-stage breast cancer. The aim of this analysis was to evaluate the cost-effectiveness of using the assay to inform adjuvant chemotherapy decisions in Germany.     

A network meta-analysis to compare simeprevir with boceprevir and telaprevir in combination with peginterferon-α and ribavirin in patients infected with genotype 1 Hepatitis C virus

Abstract

Objective:

To conduct a network meta-analysis (NMA) to assess the relative efficacy and safety of simeprevir, a second generation oral protease inhibitor (PI), compared to telaprevir and boceprevir in combination with pegylated interferon-α and ribavirin (PR) in patients with chronic hepatitis C.     

Burden of illness: direct and indirect costs among persons with hemophilia A in the United States

Abstract

Objective:

To examine the direct and indirect costs of hemophilia care among persons with hemophilia A in the US.     

Clinical simulation model of long-acting opioids for treatment of chronic non-cancer pain in the United States

Abstract

Objective:

To evaluate costs and outcomes associated with initial tapentadol ER vs oxycodone CR for the treatment of chronic non-cancer pain (CNCP) in the US.     

Prevalence and healthcare costs of obesity-related comorbidities: evidence from an electronic medical records system in the United States

Abstract

Objective:

This study estimated the economic burden of obesity-related comorbidities (ORCs) in the US, at both the person and population levels.     

Economic impact of severe and non-severe hypoglycemia in patients with Type 1 and Type 2 diabetes in the United States

Abstract

Objective:

To identify the direct and indirect costs of hypoglycemia in patients with Type 1 or Type 2 diabetes mellitus (DM) in the US setting.     

Factors associated with adherence to phosphodiesterase type 5 inhibitors for the treatment of pulmonary arterial hypertension

Abstract

Objectives:

To assess factors associated with adherence to phosphodiesterase type 5 inhibitors (PDE5Is) in the management of pulmonary arterial hypertension (PAH).     

Impact of initiation of asenapine on patterns of utilization and cost of healthcare resources associated with the treatment of bipolar I disorder

Abstract

Objective:

To assess the impact of initiation of asenapine on “real-world” levels of utilization and cost of healthcare services for the treatment of bipolar I disorder (BPD) in the US.     

Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis

Abstract

Objective:

To estimate cost per patient-year in response during 2 years following biologic initiation among patients with rheumatoid arthritis (RA).     

Costs and absence of HCV-infected employees by disease stage

Abstract

Objectives:

Quantify the costs and absenteeism associated with stages of the Hepatitis C virus (HCV).     

Cost effectiveness of paliperidone palmitate versus oral antipsychotics in patients with schizophrenia and a history of criminal justice involvement

Abstract

Objective:

Conduct a cost effectiveness analysis for the Paliperidone palmitate Research In Demonstrating Effectiveness (PRIDE) trial.     

Assessing the economic value of avoiding hospital admissions by shifting the management of gram+ acute bacterial skin and skin-structure infections to an outpatient care setting

Abstract

Objective:

To estimate, from a US payer perspective, the cost offsets of treating gram positive acute bacterial skin and skin-structure infections (ABSSSI) with varied hospital length of stay (LOS) followed by outpatient care, as well as the cost implications of avoiding hospital admission.     

Utilities for asthma and COPD according to category of severity: a comprehensive literature review

Abstract

Background:

Asthma and chronic obstructive pulmonary disease (COPD) are incurable diseases that impact quality-of-life.     

Echo-based screening of rheumatic heart disease in children: a cost-effectiveness Markov model

Abstract

Objectives:

To project the cost-effectiveness of population-based echo screening to prevent rheumatic heart disease (RHD) consequences.     

Direct and indirect healthcare resource utilization and costs associated with ulcerative colitis in a privately-insured employed population in the US

Abstract

Objective:

To assess direct and indirect healthcare resource utilization and costs of privately insured US employees with ulcerative colitis (UC) from a societal perspective.     

Assessing the role of patient support services on adherence rates in patients using glatiramer acetate for relapsing-remitting multiple sclerosis

Abstract

Objective:

To assess predictors of achievement of 80% Medication Possession Ratio (MPR) in patients receiving manufacturer-provided self-management services for relapsing-remitting multiple sclerosis (RRMS) patients taking glatiramer acetate (Copaxone).     

Challenges in economic modeling of anticancer therapies: an example of modeling the survival benefit of olaparib maintenance therapy for patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer

Abstract

Objective:

The aim of this paper is to describe a four health-state, semi-Markov model structure with health states defined by initiation of subsequent treatment, designed to make best possible use of the data available from a phase 2 clinical trial.     

Effectiveness of step therapy policies for specialty pharmaceuticals in immune disorders

Abstract

Objective:

To assess the effectiveness of managed care plans that limited access to infusion biologics via a step therapy policy.     

The effect of age and sex on cost of inpatient facility encounters among patients with multiple sclerosis

Abstract

Objective:

To explore the effect of age and sex on cost of all-cause and multiple sclerosis (MS)-related inpatient facility encounters.